T2 Biosystms Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2… Read more
T2 Biosystms Inc (TTOO) - Net Assets
Latest net assets as of September 2024: $-11.71 Million USD
Based on the latest financial reports, T2 Biosystms Inc (TTOO) has net assets worth $-11.71 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.08 Million) and total liabilities ($29.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.71 Million |
| % of Total Assets | -64.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -152.9% |
| Growth Volatility | 363.35 |
T2 Biosystms Inc - Net Assets Trend (2012–2023)
This chart illustrates how T2 Biosystms Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for T2 Biosystms Inc (2012–2023)
The table below shows the annual net assets of T2 Biosystms Inc from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-28.04 Million | +29.86% |
| 2022-12-31 | $-39.97 Million | -209.77% |
| 2021-12-31 | $-12.90 Million | -247.87% |
| 2020-12-31 | $8.73 Million | +125.66% |
| 2019-12-31 | $-34.01 Million | -398.63% |
| 2018-12-31 | $11.39 Million | +749.78% |
| 2017-12-31 | $1.34 Million | -96.59% |
| 2016-12-31 | $39.34 Million | -16.19% |
| 2015-12-31 | $46.94 Million | -11.44% |
| 2014-12-31 | $53.00 Million | +159.19% |
| 2013-12-31 | $-89.54 Million | -42.91% |
| 2012-12-31 | $-62.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to T2 Biosystms Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52163700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | % |
| Other Components | $556.26 Million | % |
| Total Equity | $-28.04 Million | 100.00% |
T2 Biosystms Inc Competitors by Market Cap
The table below lists competitors of T2 Biosystms Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BMEX Gold Inc
OTCQB:MRIRF
|
$498.87K |
|
FREEPORT MCMORAN
MU:FPMB
|
$498.94K |
|
ROSENBAUER INTERNAT
MU:ROI
|
$499.22K |
|
LeoNovus Inc
PINK:LVNSF
|
$499.27K |
|
BA-P-A
PINK:BA-P-A
|
$498.57K |
|
Bespoke Extracts Inc
OTCQB:BSPK
|
$498.21K |
|
Tortoise Energy Infrastructure Closed Fund
NYSE:TYG
|
$497.86K |
|
JUGGERNAUT EXPLOR
F:4JE1
|
$497.66K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in T2 Biosystms Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -39,969,000 to -28,036,000, a change of 11,933,000.
- Net loss of 50,077,000 reduced equity.
- New share issuances of 52,988,000 increased equity.
- Other factors increased equity by 9,022,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.08 Million | -178.62% |
| Share Issuances | $52.99 Million | +189.0% |
| Other Changes | $9.02 Million | +32.18% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares T2 Biosystms Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-447.66 | $0.12 | x |
| 2013-12-31 | $-6416.55 | $0.12 | x |
| 2014-12-31 | $610.97 | $0.12 | x |
| 2015-12-31 | $228.95 | $0.12 | x |
| 2016-12-31 | $151.21 | $0.12 | x |
| 2017-12-31 | $4.17 | $0.12 | x |
| 2018-12-31 | $28.08 | $0.12 | x |
| 2019-12-31 | $-3736.18 | $0.12 | x |
| 2020-12-31 | $359.60 | $0.12 | x |
| 2021-12-31 | $-406.11 | $0.12 | x |
| 2022-12-31 | $-783.66 | $0.12 | x |
| 2023-12-31 | $-10.74 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently T2 Biosystms Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -696.19%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-497.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -76078.95% | 0.00x | 0.00x | $-8.19 Million |
| 2013 | 0.00% | -7748.12% | 0.01x | 0.00x | $-11.66 Million |
| 2014 | -59.23% | -26378.15% | 0.00x | 1.49x | $-36.69 Million |
| 2015 | -96.49% | -1610.02% | 0.03x | 1.85x | $-49.98 Million |
| 2016 | -139.32% | -1343.24% | 0.05x | 2.28x | $-58.74 Million |
| 2017 | -4658.81% | -1337.93% | 0.09x | 40.94x | $-62.56 Million |
| 2018 | -449.22% | -487.17% | 0.16x | 5.65x | $-52.29 Million |
| 2019 | 0.00% | -757.19% | 0.29x | 0.00x | $-59.71 Million |
| 2020 | -563.92% | -271.42% | 0.23x | 9.06x | $-50.08 Million |
| 2021 | 0.00% | -190.66% | 0.46x | 0.00x | $-52.20 Million |
| 2022 | 0.00% | -284.11% | 0.65x | 0.00x | $-59.37 Million |
| 2023 | 0.00% | -696.19% | 0.21x | 0.00x | $-47.27 Million |
Industry Comparison
This section compares T2 Biosystms Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| T2 Biosystms Inc (TTOO) | $-11.71 Million | 0.00% | N/A | $498.71K |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |